Dendreon Files for Bankruptcy As Pat of Financial Restructuring

Operations to Continue Without Interruption; PROVENGE® Remains Commercially Available Commences Voluntary Chapter 11 Proceedings to Implement Restructuring Agreements November 10, 2014 Dendreon Corporation (“Dendreon” or the “Company”) today announced that it has reached agreements on the terms of a financial restructuring with certain holders (the “Senior Noteholders”) of the Company’s 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) representing …

Dendreon Plans to Make PROVENGE Available in Europe

March 3, 2014 Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom. Dendreon will make PROVENGE commercially available to patients within the approved label through Centers of Excellence using its Contract Manufacturing Organization, PharmaCell. Centers of Excellence are institutions where a high volume of prostate cancer …

Dendreon said to be hunting for buyer–will they find one?

Dendreon Corp, the manufacturers of prostate cancer vaccine Provenge, may face an uphill battle in finding a buyer, Bloomberg reports. The company is reportedly working with JPMorgan Chase to find a buyer, but analysts have said that intensifying competition and disappointing sales of Provenge may mean potential suitors are unlikely to come forward. One of the problems Dendreon has had …

Good news for Dendreon, Provenge gets EU approval

After a troubled time across the pond, Dendreon has been granted European marketing authorisation for its prostate cancer vaccine Provenge. The immunotherapy, also known as sipuleucel-T, got the final approval from the European Commission yesterday, following recent thumbs-ups from the EMA's Committee for Advanced Therapy (CAT) and the Committee for Medicinal Products for Human  Use (CHMP). The marketing authorisation was …